Product liability
This article was originally published in The Tan Sheet
Executive Summary
Senate does not agree to close debate on S 687 on June 29, effectively killing the bill for this congressional session. After losing two cloture votes on the bill, which would establish a uniform product liability code, bill supporters succumbed to a filibuster in the face of the Senate's tight legislative schedule. Following a first cloture vote June 28, which failed 54-44, chief sponsor Sen. Jay Rockefeller (D-W.Va.) agreed to support an amendment offered by Sens. Byron Dorgan (D-N.D.) and Carol Moseley-Braun (D-Ill.) to eliminate a provision of S 687 that would limit liability for punitive damages for makers of drugs or devices that have received premarket approval from FDA. However, a second cloture vote failed 57-41 before the amendment could be brought up for a vote
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning